


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Original) A compound of formula I, or a pharmaceutically acceptable salt thereof,



I

wherein:

Z¹ is N or CH;

Z² and Z³ are each independently N or CR⁷;

R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ are each independently H, R⁸, or R⁹;

each R⁸ is independently a hydrocarbyl group; and

each R⁹ is independently halo, NO₂, alkoxy, CN, CF₃, SO₃H, SO₂NR¹⁰R¹¹, SO₂R¹²,

NR¹³R¹⁴, (CH₂)_aCOOR¹⁵, (CH₂)_bCONR¹⁶R¹⁷, (CH₂)_cCOR¹⁸ or (CH₂)_dOH;

a, b, c and d are each independently 0, 1 2 3 or 4;

R¹⁰⁻¹⁸ are each independently H or alkyl;

provided that when R¹ and R² are both H,

Z¹ is CH; or

Z² is N; or

Z¹ is CH and Z² is N;

and wherein the compound is other than 4-(4,5-dimethylthiazol-2-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine or 4-(5-(2-hydroxyethyl)-4-methylthiazol-2-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine.

2. (Original) A compound according to claim 1 wherein each R⁸ is independently a C₁₋₃₀ hydrocarbyl group, optionally containing up to twelve heteroatoms selected from N, S, and O, and optionally bearing up to six substituents each independently selected from halo, NO₂, CN, CF₃, SO₃H, SO₂NH₂, SO₂Me, OH, NH₂, COOH, and CONH₂.

3. **(Currently Amended)** A compound according to claim 1 or ~~claim 2~~ wherein each R⁸ is independently an alkyl group, an aryl group or a cycloheteroalkyl group.

4. **(Currently Amended)** A compound according to claim 1 or ~~claim 2~~ wherein each R⁹ is independently halo, NO₂, alkoxy, CN, CF₃, SO₃H, SO₂NH₂, SO₂Me, OH, NH₂, (CH₂)_aCOOR¹⁵, (CH₂)_dOH, CONH₂ or COR¹⁸.

5. **(Currently Amended)** A compound according to ~~any preceding~~ claim 1 wherein:
R¹ is H, alkyl, aryl, (CH₂)_aCOOR¹⁵ or OH;
R² is H, (CH₂)_dOH, (CH₂)_aCOOR¹⁵, COR¹⁸ or alkyl;
R³ is halo, H, alkoxy, cycloheteroalkyl, alkyl or OH;
R⁴ is H, NH₂, OH, alkyl, CF₃ or NO₂; and
R⁵ and R⁶ are both H.

6. **(Currently Amended)** A compound according to ~~any preceding~~ claim 1 wherein:
R¹ is H, Me, Ph, CH₂COOMe or OH;
R² is H, (CH₂)₂OH, COOEt, COMe or Me;
R³ is Cl, H, OMe, N-morpholinyl, N-pyrrolidinyl, Me or OH;
R⁴ is H, NH₂, OH, Me, CF₃ or NO₂; and
R⁵ and R⁶ are both H.

7. **(Original)** A compound according to claim 1 wherein Z¹ is CH and Z² and Z³ are each independently N or CR⁷.

8. **(Original)** A compound according to claim 7 wherein Z² and Z³ are each independently CR⁷.

9. **(Currently Amended)** A compound according to claim 7 or ~~claim 8~~ wherein;
R¹ is alkyl or OH;
R² is alkyl or COR¹⁸;
R³ is OH or halo; and
Z² and Z³ are both CH.

10. **(Original)** A compound according to claim 9 wherein R¹ is Me or OH, R² is COMe or Me, and R³ is OH or Cl.

11. (**Original**) A compound according to claim 1 wherein Z¹ is N and Z² and Z³ are each independently N or CR⁷.

12. (**Original**) A compound according to claim 11 wherein Z² and Z³ are each independently CR⁷.

13. (**Original**) A compound according to claim 12 wherein:

R¹ is alkyl, aryl, OH or (CH₂)_aCOOR¹⁵;

R² is COR¹⁸, H, COOR¹⁵ or alkyl;

R³ is halo, H, OH, alkyl or morpholino;

R⁴ is H, NH₂, OH, CF₃ or NO₂; and

Z² and Z³ are both CH.

14. (**Original**) A compound according to claim 13 wherein:

R¹ is Me, Ph, OH or CH₂COOMe;

R² is COMe, H, COOEt or Me; and

R³ is halo, H, OH, alkyl or morpholino.

15. (**Original**) A compound according to claim 11 wherein Z² is N and Z³ is CR⁷.

16. (**Original**) A compound according to claim 15 wherein:

R¹ is H, OH or alkyl;

R² is H, (CH₂)_dOH, alkyl, (CH₂)_aCOOR¹⁵, COR¹⁸;

R³ is halo, alkoxy or heterocycloalkyl;

R⁴ is H or alkyl; and

Z³ is CH.

17. (**Original**) A compound according to claim 16 wherein:

R¹ is H, OH or Me;

R² is H, (CH₂)₂OH, Me, COOEt, COMe;

R³ is halo, OMe or N-pyrrolidinyl;

R⁴ is H or Me; and

Z³ is CH.

18. (**Original**) A compound according to claim 1 which is selected from the following:

1-{2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-5-yl}-ethanone

(4-Chloro-phenyl)-[4-(4-methyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
(4-Chloro-phenyl)-[4-(4-phenyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazole-5-carboxylic acid ethyl ester
{2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-thiazol-4-yl}-acetic acid methyl ester
2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester
N-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-benzene-1,3-diamine
3-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-[3-trifluoromethyl-phenyl]-amine
(4-Chloro-3-trifluoromethyl-phenyl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-[3-nitro-phenyl]-amine
(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
1-{2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-methyl-thiazol-5-yl}-ethanone
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-[6-methoxy-pyridin-3-yl]-amine
(6-Chloro-pyridin-3-yl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-[4-morpholin-4-yl-phenyl]-amine
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-[4-methyl-3-nitro-phenyl]-amine
4-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol
(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol
2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol
(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.

19. (Original) A compound according to claim 1 which is selected from the following:

2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester;
N-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-benzene-1,3-diamine
3-[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-ylamino]-phenol
[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-[3-trifluoromethyl-phenyl]-amine

(4-Chloro-3-trifluoromethyl-phenyl)-[4-(4,5-dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-amine

(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

[4-(4,5-Dimethyl-thiazol-2-yl)-pyrimidin-2-yl]-(6-methoxy-pyridin-3-yl)-amine

2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol

(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol

(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.

20. (Original) A compound according to claim 1 which is selected from the following:

2-[2-(4-Chloro-phenylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester;

(6-Methoxy-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine; and

(6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

2-[2-(4-Chloro-phenylamino)-pyridin-4-yl]-5-methyl-thiazol-4-ol

(6-Pyrrolidin-1-yl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-4-hydroxy-thiazole-5-carboxylic acid ethyl ester

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-methyl-thiazol-4-ol

2-[2-(6-Chloro-pyridin-3-ylamino)-pyrimidin-4-yl]-5-(2-hydroxy-ethyl)-thiazol-4-ol

(6-Chloro-5-methyl-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine

21. (Original) A compound according to claim 1 which is (6-Chloro-pyridin-3-yl)-(4-thiazol-2-yl-pyrimidin-2-yl)-amine.


22. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any preceding~~ claim 1 admixed with a pharmaceutically acceptable diluent, excipient or carrier.

Claims 23-41 (Canceled).


42. (Currently Amended) Use of a compound according to ~~any one of~~ claims 1 to 21 in an assay for identifying further candidate compounds capable of inhibiting one or more of a cyclin dependent kinase, aurora kinase, GSK and a PLK enzyme.

43. (Currently Amended) Use according to claim 4238 wherein said assay is a competitive binding assay.

44. (Original) A process for preparing a compound of formula I as defined in claim 1, said process comprising reacting a compound of formula 9 with a compound of formula 10 to form a compound of formula I, wherein R¹⁻⁶ are as defined in claim 1



45. (Original) A process for preparing a compound of formula I as defined in claim 1, said process comprising reacting a compound of formula 15 with a compound of formula 3 to form a compound of formula I, wherein R¹⁻⁶ are as defined in claim 1



46. (New) A method of treating a proliferative disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the proliferative disorder is treated.

47. (New) The method of claim 46, wherein the proliferative disorder is cancer or leukemia.

48. (**New**) The method of claim 46, wherein the proliferative disorder is glomerulonephritis, rheumatoid arthritis, psoriasis or chronic obstructive pulmonary disorder.
49. (**New**) A method of treating a viral disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the viral disorder is treated.
50. (**New**) The method according to claim 49, wherein the viral disorder is selected from human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), human immunodeficiency virus type 1 (HIV-1), and varicella zoster virus (VZV).
51. (**New**) A method of treating a CNS disorder, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the CNS disorder is treated.
52. (**New**) The method according to claim 51, wherein the CNS disorder is Alzheimer's disease or bipolar disorder.
53. (**New**) A method of treating alopecia, said method comprising administering to a subject in need thereof, a compound of claim 1, such that alopecia is treated.
54. (**New**) A method of treating a stroke, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the stroke is treated.
55. (**New**) The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit at least one PLK enzyme.
56. (**New**) The method according to claim 55, wherein the PLK enzyme is PLK1.
57. (**New**) The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit at least one CDK enzyme.
58. (**New**) The method according to claim 57, wherein the CDK enzyme is CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK8 and/or CDK9.
59. (**New**) The method according to claim 46, wherein the compound is administered in an amount sufficient to inhibit aurora kinase.

60. (**New**) A method of treating diabetes, said method comprising administering to a subject in need thereof, a compound of claim 1, such that diabetes is treated.

61. (**New**) The method according to claim 60, wherein the diabetes is non-insulin-dependent diabetes or Type II diabetes.

62. (**New**) The method according to claim 60, wherein the compound is administered in an amount sufficient to inhibit GSK.

63. (**New**) The method according to claim 62, wherein the compound is administered in an amount sufficient to inhibit GSK3 β .

64. (**New**) A method of treating an inflammatory disease, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the inflammatory disease is treated.

65. (**New**) A method of treating an infectious disease, said method comprising administering to a subject in need thereof, a compound of claim 1, such that the infectious disease is treated.